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Abstract
Background: The West-African (WA) Zaire Ebolavirus disease (EVD) outbreak was characterized by an exceptionally
high number of cases and deaths as compared with the Eastern-Central African (ECA) outbreaks. Despite the Zaire
Ebolavirus being the most lethal for humans, case-fatality rate, close to 80 % in ECA outbreaks, almost halved to
47 % in Guinea-Liberia-Sierra Leone (WA). Such an improvement was due to the remarkable implementation of
international humanitarian aids. Some studies also suggested that the long human-to-human transmission cycle
occurred in WA, gave rise to human adaptation and consequent immune escape. Haemorrhage, the main feature
in seriously infected EVD patients, is due to the immune system that triggers the infected endothelial cells which
expose the spike-like glycoprotein (GP) of the virion on their surface. If the human adaptation hypothesis holds
true, the proportion of EVD patients with haemorrhage in the WA outbreak should be lower than in the ECA
outbreaks due to immune escape. Therefore, the aim of this meta-analysis was to compare the relative frequencies
of three typical haemorrhagic symptoms (conjunctival –CB, nasal –NB, gingival –GB- bleedings) in the ECA and WA
outbreaks.
Methods: Literature searches were performed through PubMed and Scopus using generic keywords; surveys
including at least ten patients reporting CB, NB, GB relative frequencies were extracted and split into ECA and WA.
The meta-analytical methods chosen were based on the levels of between-study heterogeneity and publication
bias. Pooled CB, NB, GB relative frequencies in ECA and WA were estimated and compared. Subgroup analysis
including only studies on Zaire Ebolavirus also was performed.
Results: Fifteen studies (10 ECA, 5 WA) were located with 4,867 (CB), 3,859 (NB), 4,278 (GB) EVD patients overall. GB
pooled relative frequency was 45.3 % (95 % confidence interval -95 CI, 34.7–56.1 %) and 18.0 % (95 CI, 6.0–34.5 %),
in ECA and WA; NB was 10.6 % (95 CI, 5.7–16.8 %) and 1.3 % (1.0–1.8 %); GB was 24.2 % (95 CI, 11.9–39.2 %) and
1.9 % (95 CI, 1.4–2.4 %). Subgroup analysis confirmed these results.
Conclusions: During the WA outbreak the relative frequency of GB decreased by two thirds, while NB and GB
almost disappeared, suggesting that the Zaire Ebolavirus human adaptation hypothesis is plausible.
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Background
Ebolavirus disease (EVD) is a zoonosis with persistence of
the virus in reservoir species. Indeed, at least three species
of fruit bats (suborder Megachiroptera) are naturally in-
fected: Hypsignathus monstrosus (hammer-headed fruit
bat), Epomops franqueti (singing fruit bat) and Myonycteris
torquata (little collared fruit bat). Asymptomatically-
infected bats drop partially eaten fruit and masticated fruit
pulp, contaminated by their saliva and blood, to the
ground, where they are eaten by great apes and forest
duikers (antelopes). Ebolavirus may then be transmitted
from these infected animals to humans. Humans and pri-
mates have been considered the end hosts and have not
been regarded as reservoir species [1]. Ebolavirus is trans-
mitted between humans through direct contact with blood
or blood-containing vomit, faeces and other bodily fluids
(or tissues) from EVD patients in the acute stage of the
disease. Conversely, subjects who reside in confined,
shared and close spaces, but who have no direct physical
contact with acute cases, do not develop EVD [2–4].
Transmission through air is unlikely [5, 6], while sexual
transmission through infected patients is possible [7].
EVD has an incubation period of 2–21 days and the main
symptoms are fever, headache, fatigue, myalgia, diarrhoea,
vomiting, abdominal pain and, typically, bleeding includ-
ing conjunctival, nasal, gingival bleeding and bleeding
from skin and injection sites [8, 9]. Recovery may be
followed by muscle pains and prolonged virus carriage.
The first cases of EVD were reported in 1976 in
southern South Sudan and in the northern Democratic
Republic of the Congo [10, 11]. Since 1976, human-to-
human transmission has been reported in several
Eastern-Central African outbreaks [12]. The latest EVD
outbreak started in Guinea (West Africa), the index case
was a 18-month-old boy died in December 2013, but
the outbreak was not detected until March 2014, thus
leaving thousands of people becoming infected. In this lar-
gest outbreak ever seen, the case number was 100–1000
times greater than in previous outbreaks [13]. Assuming
that the EVD attack rate did not change significantly from
previous outbreaks [11, 14–16] and that in the early stages
of the West African outbreak the Ebolavirus did not
undergo important genetic changes affecting transmission
rate [17–19], such an increase was probably explained by
the exceptional human crowding due to both the urban
setting and the generally higher population density in
West Africa than in Eastern-Central Africa [20], which led
to a large increase in the number of exposed individuals.
In addition to human crowding there were other social de-
terminants explaining the West-African outbreak, which,
according to the World Health Organization (WHO),
were: (1) Extremely damaged Public Health infrastructures
in Guinea, Liberia and Sierra Leone, which only recently
emerged from years of civil war; (2) High population
mobility across uncontrolled borders, another consequence
of war; (3) Severe shortages of trained healthcare workers:
before the 2013–2015 outbreak there were 1–2 doctors
every 100,000 individuals; (4) Cultural beliefs and behav-
ioral practices, such as the adherence to ancestral funeral
and burial practices. The WHO has estimated that 60-80 %
EVD cases were attributable to these practices; (5) Reliance
on traditional healers: as the outbreak began, the high EVD
mortality in healthcare facilities inducing local people to
think that hospitals were the places where contagion and
death actually occur; (6) Community resistance: many
people refused to believe that EVD was real because they
and their ancestors had been living in the same environ-
ment and had never developed EVD before; (7) Public
Health messages that were intended to promote protective
behaviors proved to have the opposite effect, because they
emphasized that the disease was extremely serious and
there was no vaccine or treatment; (8) Other endemic in-
fectious diseases, such as cholera and malaria, which can be
difficult to distinguish from EVD in the early stages; (9)
Ebolavirus is endemic in West Africa; and (10) Spread by
international air travel [21].
Genome surveillance studies revealed that while dur-
ing the Eastern-Central African outbreaks the Ebolavirus
evolution rate was 0.5-8 × 10−4 nucleotide substitutions
per site per year [22], in West Africa such a rate raised
to 9–20 × 10−4 nucleotide substitutions per site per year
[17, 22–25] showing an accelerated evolution. In
addition, many nonsynonymous nucleotide substitutions
occurred on the surface of the spike-like glycoprotein
(GP; which plays an important role in the virus entry
into cells) [26] and promoted immune evasion [27].
These data support the hypothesis that after a series of
tragic coincidences due to environmental factors, which
promoted the spread of the outbreak, the persistence of
the human-to-human transmission cycle gave raise to
genetic changes which caused the generation of several
lineages and to human adaptation [27]. This hypothesis
is corroborated by the facts that similar trends have been
observed for other cell receptor binding enzymes, such
as the neuraminidase of the influenza virus subtypes A
H1N1 and A H3N2 [28] and that a similar intra-
individual evolution occurs to the envelope glycoprotein
of hepatitis C virus after the acute phase of the infection
to escape from the host immune response and establish
persistent (i.e., chronic) infection [29, 30].
Another element in support of this hypothesis is the
change in case-fatality rate. Indeed, Zaire Ebolavirus is
the most lethal species with an estimated case-fatality
rate of 76 %, considerably higher than the Sudan (55 %)
and the Bundibugyo (37 %) species [31]. During the lat-
est Zaire Ebolavirus outbreak the case-fatality rate
dropped to 47 % (considering only confirmed cases and
deaths in Guinea and Sierra Leone) [13]. Such a decrease
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in case-fatality rate is typical of human adaptation [28]
and is in line with the theory that the majority of human
pathogens arose only after the advent of agriculture and
originate from animal pathogens: they were initially re-
sponsible for zoonoses and later adapted to the human
hosts, due to co-habitation between animals and humans
and to human crowding [32]. The reported decrease in
EVD case-fatality rate during the West-African EVD out-
break is, however, principally due to the prompt imple-
mentation of control and therapeutic measures by local
and international organizations from all over the world
(see, https://en.wikipedia.org/wiki/Responses_to_the_Ebo-
la_virus_epidemic_in_West_Africa for review. Accessed
August 24, 2015).
Haemorrhage is a serious EVD consequence, often re-
sponsible for patients' demise. Actually, during the first
EVD outbreak in South Sudan, almost all (91 %) of the
fatal cases and only one half (48 %) of the nonfatal cases
showed some visible bleeding features [10]. This link be-
tween the onset of haemorrhage and death is due to the
fact that Ebolavirus primarily infects endothelial cells.
GP is responsible for virus internalization and is then
displayed on the external surface of the infected cells.
Haemorrhage is, therefore, due the lysis of infected
endothelial cells caused by the human immune system
triggered by GP [33].
Therefore, given the association between death and
haemorrhage in EVD patients, in order to evaluate
whether the large decrease in case-fatality rate observed
during the West African outbreak was exclusively due to
humanitarian aids or could be explained by Ebolavirus
human adaptation, the current study sought to investigate
the relative frequency of EVD patients with haemorrhagic
features. More specifically, if the immune evasion hypoth-
esis holds true, patients with haemorrhage should be less
frequent during the West-African outbreak than during
the Eastern-Central African outbreaks. If, alternatively,
Ebolavirus adaptation to humans did not occur in West
Africa, the frequency of EVD patients with haemorrhage
did not vary. Thus, this meta-analysis sought to esti-
mate the pooled relative frequencies of conjunctival
and orofacial (nasal, gingival) haemorrhagic symptoms
observed during the earlier Eastern-Central African
and the latest West African outbreaks.
Methods
A meta-analysis was performed to estimate the pooled rela-
tive frequency of the three main orofacial haemorrhagic
symptoms/signs, that is, conjunctival bleeding/injection
(and conjunctivitis), epistaxis and gingival bleeding, features
chosen because they are easily detectable, although they are
not exclusive of EVD. It was assumed that the other
conditions and diseases associated with similar symptoms
(e.g. gingivitis) did not change in frequency within the study
populations throughout these years and, therefore, did not
interfere with the present analysis.
Literature searches were performed through Scopus and
PubMed without time and language restrictions. Inclusion
criteria were surveys reporting conjunctival, nasal and/or
gingival bleeding in samples of at least ten EVD patients.
Exclusion criteria were all non-relevant studies (e.g., stud-
ies on animals, laboratory studies, reviews, etc.), case
reports/samples of less than ten EVD patients, surveys
which did not report bleeding features analytically.
Generic key words were used to minimize selection
bias which, in meta-analyses, refers to undetected
published studies. Selection bias was considered more
pervasive than publication bias, which refers to unpub-
lished studies, due to the recent explosion of scientific
journals and publications [34]. Thus, key words used
were “Ebola” (title, abstract, key words) AND “symptom”
(all fields).
Titles and abstracts were used to exclude non-relevant
studies. Full texts of remaining surveys were searched
and read and only surveys which met the inclusion
criteria were selected. The reviewers independently ex-
tracted conjunctival bleeding (EMV), epistaxis (LTM)
and gingival bleeding (GAM) relative frequencies. Ex-
tracted data were then supervised and meta-analyzed by
the two other authors (SP and CS).
The pooled relative frequencies of the three features
were assessed. The meta-analytic method was chosen on
the basis of the level of between-study heterogeneity,
which was investigated with the I2 statistic [35]. For
non-significant I2 values the meta-analysis was performed
with the fixed-effects method, for significant I2 values the
random-effects method was used.
Publication bias was formally investigated [36] with the
test of Egger and colleagues [37], if the test was significant
the number of studies was adjusted for publication bias
using the trim and fill method and identifying the poten-
tially missing studies with the R0 method [38, 39].
Sensitivity analysis to study inclusion was made to in-
vestigate whether the pooled relative frequency estimates
were influenced by a single study.
Surveys were then split according to the country
where they have been performed into Eastern-Central
African and West African outbreaks. Pooled relative fre-
quency estimates of conjunctival nasal and gingival
bleeding were assessed for these subgroups using the
aforementioned methodology.
Studies on conjunctival bleeding were split into
studies which reported bleeding or injected eyes (con-
junctival bleeding) and studies which reported more
generic conjunctivitis. Pooled relative frequency esti-
mates were assessed for all studies together, for
Eastern-Central African studies and for West African
studies.
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Subgroup analysis also was performed to investigate
whether there were differences between Zaire Ebolavirus
outbreaks. Therefore, since the West-African outbreak
was exclusively due to the Zaire Ebolavirus species,
surveys from Eastern-Central Africa reporting only Zaire
Ebolavirus outbreaks were considered and the pooled
relative frequency estimates of conjunctival nasal and
gingival bleeding were assessed.
This article followed the MOOSE guidelines for
reporting meta-analyses of observational studies [40].
The statistical analyses were performed using StatView
5.0.1 (SAS Institute Inc., NC,US). The level of signifi-
cance was set at 95 %.
Results
The Scopus and PubMed searches, performed on October
15, 2015, provided 130 and 691 studies, respectively
(Fig. 1). Most of the studies did not fall into the inclusion
criteria, thus leaving twenty-one eligible studies. Four of
these were excluded because bleeding features were re-
ported cumulatively [10, 41–43], one because the relative
frequency was not reported [44], another one because it
was part of a larger sample [45], thus fifteen primary stud-
ies were available for meta-analysis [2, 11, 46–58]. All
studies were performed during Zaire Ebolavirus out-
breaks, excluding two studies performed during Sudan
Ebolavirus [2, 51] and one study during a Bundibugyo
Ebolavirus [52] (Table 1) outbreak. Five studies were
performed during the West African outbreak [54–58], the
remainder during the Eastern-Central African outbreaks.
The number of EVD patients considered for conjunc-
tival bleeding were 4,867 (677 from Eastern-Central
Africa, 4,190 from West Africa), those considered for
nasal bleeding were 3,859 (522 from Eastern-Central
Africa, 3,337 from West Africa), those considered for
gingival bleeding were 4,278 (972 from Eastern-Central
Africa, 3,306 from West Africa) (Additional file 1:
Table S1). The relative frequencies of conjunctival
nasal and gingival bleeding reported by the primary
studies are displayed in Table 2. Conjunctival bleeding
was reported by thirteen studies, epistaxis by ten stud-
ies, gingival bleeding by eleven studies.
Between-study heterogeneity was significantly high for
all these features (Table 3). Therefore, the random-
Fig. 1 PRISMA 2009 flow diagram of primary study selection procedure
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effects method was used. According to the test of Egger
and colleagues, the degree of publication bias was not
significantly high and no adjustment was performed
(data not in Table). The Forest plots (Additional file 2:
Figure S1) including all studies show that relative
frequency of conjunctival bleeding apparently decreased
from the oldest to the newest study (Additional file 2:
Figure S1a), the same trends were observed for epistaxis
(Additional file 2: Figure S1b) and gingival bleeding
(Additional file 2: Figure S1c). The pooled relative fre-
quency estimates showed that conjunctival bleeding/
conjunctivitis was the most frequent feature and was re-
ported in 34 % (95 % confidence interval, 23–45 %) EVD
patients, followed by gingival bleeding (21 %; 95 % confi-
dence interval, 7–40 %) and epistaxis (9 %; 95 % confi-
dence interval 3–16 %). Conjunctival bleeding/
conjunctivitis was significantly more frequent than epi-
staxis, while the differences between the other features
were not significant (Table 3). Sensitivity analysis to ex-
clusion criteria corroborated these estimates, since none
of the studies, excluded in turn, produced a statistically
significant departure from the estimates obtained with
Table 1 Characteristics of the outbreaks described by the primary studies
Study Ebolavirus Country Survey year
WHO, [11] Zaire Democratic Republic of Congo 1976
Baron et al., [2] Sudan South Sudan 1979
Sureau, [46] Zaire Democratic Republic of Congo 1976
Bwaka et al., [47] Zaire Democratic Republic of Congo 1995
Georges et al., [48] Zaire Gabon 1996
Khan et al., [49] Zaire Democratic Republic of Congo 1995
Ndambi et al., [50] Zaire Democratic Republic of Congo 1995
Mupere et al., [51] Sudan Uganda 2000
Roddy et al., [52] Bundibugyo Uganda 2007
Maganga et al., [53] Zaire Democratic Republic of Congo 2014
Schieffelin et al., [54] Zaire Sierra Leone 2014
Bah et al., [55] Zaire Guinea 2014
Dallatomasina et al., [56] Zaire Sierra Leone 2014
WHO Ebola Response Team, [57] Zaire Guinea, Liberia, Sierra Leone 2014
Yan et al., [58] Zaire Sierra Leone 2014
Table 2 Relative frequencies (95 % confidence intervals between parentheses) of conjunctival, nasal and gingival bleeding features
reported by the primary studies
Study Conjunctival bleeding and conjunctivitis Nasal bleeding Gingival bleeding
WHO, [11] 55.0 % (48.5–61.3 %) 67.4 % (61.4–73.3 %)
Baron et al., [2] 21.9 % (7.6–36.2 %) 34.4 % (17.9–50.8 %)
Sureau, [46] 14.7 % (10.5–19.0 %) 22.3 % (17.3–27.3 %)
Bwaka et al., [47] 42.7 % (33.0–52.8 %) 1.9 % (0.0–4.6 %) 12.6 % (6.2–19.0 %)
Georges et al., [48] 53.3 % (26.6–78.7 %) 13.3 % (0.0–30.5 %) 40.0 % (15.2–64.8 %)
Khan et al., [49] 35.7 % (29.2–42.6 %) 22.1 % (16.5–27.8 %)
Ndambi et al., [50] 78.3 % (56.3–92.5 %) 4.3 % (0.0–12.7 %) 30.4 % (11.6–49.2 %)
Mupere et al., [51] 40.0 % (19.1–63.9 %) 10.0 % (0.0–23.1 %) 10.0 % (0.0–23.1 %)
Roddy et al., [52] 50.0 % (29.9–70.1 %) 7.7 % (0.0–17.9 %) 3.8 % (0.0–11.2 %)
Maganga et al., [53] 15.8 % (6.0–31.3 %) 10.5 % (0.8–20.3 %) 7.9 % (0.0–16.5 %)
Schieffelin et al., [54] 25.0 % (13.2–40.3 %)
Bah et al., [55] 10.8 % (3.0–25.4 %) 5.4 % (0.0–12.7 %)
Dallatomasina et al., [56] 2.0 % (0.7–4.7 %)
WHO Ebola Response Team, [57] 26.0 % (24.6–27.4 %) 1.3 % (0.9–1.7 %) 1.9 % (1.4–2.4 %)
Yan et al., [58] 34.3 % (25.4–44.0 %)
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all the primary studies included (Additional file 3:
Table S2). The difference between conjunctivitis and
conjunctival bleeding/injection was non-significant:
36 % (95 % confidence interval, 21–52 %) and 31 %
(95 % confidence interval 21–42 %).
Studies performed during the Eastern-Central African
outbreaks were eight for conjunctival bleeding [10, 47–53]
and epistaxis [2, 46–48, 50–53], ten for gingival bleeding
[2, 10, 46–53], while studies performed during the West
African outbreak were five for conjunctival bleeding
[54–58], two for epistaxis [55, 57] and one for gingival
bleeding [57]. The random-effects method was used in
almost all cases. The Forest plots including only Eastern-
Central African studies were regularly distributed across
the pooled estimates (Additional file 4: Figure S2). Fairly
irregular distributions were observed for West African
studies, due to their limited number. Conjunctival nasal
and gingival bleeding features were significantly more fre-
quent in the Eastern-Central African studies (Table 4).
Conjunctival bleeding pooled relative frequency was 45 %
in Eastern-Central Africa (95 % confidence interval,
35–56 %) and 18 % in West Africa (95 % confidence
interval, 6–34 %); epistaxis was 11 % in Eastern-
Central Africa (95 % confidence interval, 6–17 %) and
only 1 % in West Africa (95 % confidence interval, 1–2 %);
gingival bleeding was 24 % in Eastern-Central Africa
(95 % confidence interval, 12–39 %) and only 2 % in West
Africa (95 % confidence interval, 1–2 %).
Eastern-Central African studies focusing on Zaire
Ebolavirus outbreaks were six for conjunctival bleeding
[10, 47–50, 53], five for epistaxis [46–48, 50, 53], seven
for gingival bleeding [10, 46–50, 53]. The random-
Table 3 Pooled relative frequency estimates of conjunctival, nasal and gingival bleeding features. Between–study heterogeneity
(I2 statistic, 95 % confidence interval)
Bleeding Pooled relative frequency 95 % confidence interval I2 statistic
Conjunctival (all) 33.6 % 23.5–44.6 % 94.6–97.2 %
Conjunctivitis only 35.9 % 20.9–52.5 % 96.4–98.3 %
Conjunctival bleeding/injection 31.1 % 21.3–41.8 % 42.1–90.3 %
Nasal 8.7 % 3.5–16.0 % 87.8–95.1 %
Gingival 21.1 % 7.0–40.1 % 98.4–99.0 %
Table 4 Pooled relative frequency estimates of conjunctival, nasal and gingival bleeding features in the Eastern–Central African
outbreaks (all outbreaks, Zaire Ebolavirus outbreaks) and in the West–African outbreak. Between–study heterogeneity (I2 statistic,
95 % confidence interval)
Pooled relative frequency 95 % confidence interval I2 statistic
Conjunctival bleeding/injection and conjunctivitis
Eastern–Central Africa (8 studies) 45.3 % 34.7–56.1 % 70.7–91.6 %
Eastern–Central Africa (Zaire Ebolavirus, 6 studies) 45.4 % 32.6–58.4 % 77.9–94.2 %
West Africa (5 studies) 18.0 % 6.0–34.5 % 95.6–98.3 %
Conjunctival bleeding/injection only
Eastern–Central Africa (3 studies) 38.2 % 33.0–43.6 % 0.0–95.5a
West Africa (2 studies) 18.8 % 11.0–28.8 % 0.0–91.3a
Conjunctivitis only
Eastern–Central Africa (5 studies) 50.0 % 31.0–68.2 % 72.0–94.0 %
West Africa (3 studies) 17.9 % 3.0–41.5 % 95.6–99.2 %
Nasal bleeding
Eastern–Central Africa (8 studies) 10.6 % 5.7–16.8 % 33.1–84.8 %
Eastern–Central Africa (Zaire Ebolavirus, 5 studies) 9.0 % 3.3–17.2 % 47.7–90.9 %
West Africa (2 studies) 1.3 % 1.0–1.8 % 0.0–92.8 %a
Gingival bleeding
Eastern–Central Africa (10 studies) 24.2 % 11.9–39.2 % 93.6–97.0 %
Eastern–Central Africa (Zaire Ebolavirus, 7 studies) 27.9 % 12.5–46.7 % 95.1–97.9 %
West Africa (1 study) 1.9 % 1.4–2.4 % Not applicableb
anon–significant I2statistic, fixed–effects meta–analytic method; bprevalence estimate reported by a single study
All the differences between pooled relative frequencies in Eastern–Central Africa and West Africa are statistically significant at 95 % level
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effects method was used due to large between-study
heterogeneity (Table 4). No adjustment for publication
bias was performed because of regular distribution of
the studies in the Forest plots (data not shown). Pooled
relative frequencies of conjunctival, nasal and gingival
bleeding were 45 % (95 % confidence interval, 33–58 %),
9.0 % (95 % confidence interval, 3–17 %), 28 % (95 % con-
fidence interval, 12–47 %), respectively. Differences with
the West African outbreak were significant at 95 % level.
Discussion
One problem in assessing the relative frequency of
EVD haemorrhagic signs is that features were re-
ported by healthcare workers when the patients pre-
sented at the healthcare facilities and therefore,
depend on the disease stage at presentation (which, in
turn, depends on the level of the population aware-
ness toward EVD) and on the reporting protocol
adopted by the healthcare staff. Although there are no
elements to support this hypothesis, it is reasonable to con-
jecture that if the general population was unaware of EVD
features, infected subjects with epistaxis, gingival bleeding
and/or conjunctival bleeding as main features were less
likely to present to healthcare facilities than were subjects
more obviously ill with high fever, vomiting and/or diar-
rhoea. Few of the healthcare workers would be trained
specifically in ENT/Ophthalmology and/or Dental exami-
nations, and facilities for these were likely uncommon.
Thus, primary studies must yield some degree of reporting
bias, which probably led to underestimate the true relative
frequencies of the these bleeding features. However, if
reporting bias was present in the African healthcare
facilities, it was probably lower in the studies used for this
meta-analysis, because authors often followed the WHO
EVD case definition recommendations, which comprised
gingival bleeding and conjunctivitis among the key
features [59].
Another issue with the present meta-analysis was
selection bias, which usually refers to published studies
that have not been located. In this analysis it may also
refer to the inclusion of partially duplicate studies, which
reported data from the same sets of patients and to the
exclusion of studies which were mistakenly considered
duplicate and actually were original. This problem
regards principally the West African outbreak, due to
the exceptionally high number of published studies. In
order to obtain the most reliable pooled estimates, the
risk to exclude potentially original studies was preferred
to the risk to reuse data from the same set of patients.
Indeed, in the first case, the limited number of patients
led to broader confidence intervals, while in the latter
case, the inclusion of duplicate data may have raised the
burden of the bias of the primary study, in the event that
there was any.
The present analysis suggests that conjunctival bleeding
is the most frequent EVD orofacial symptom. However, it
is not possible to diagnose EVD solely on the basis of con-
junctival bleeding even if fever, vomiting and diarrhoea are
co-existing, because these features are frequently present
in many infectious diseases common in Eastern-Central
and West Africa, such as measles [60] and malaria [61].
Very interestingly, conjunctival bleeding/injection along
with conjunctivitis, which were detected in almost one
half EVD patients during the Eastern-Central African out-
breaks, were reported in less than one every six patients
during the West African outbreak. As for the two other
investigated features, they were detected relatively fre-
quently during Eastern-Central African outbreaks, that is,
one every four patients (gingival bleeding) and one every
ten patients (epistaxis), while they were almost non-
existent during the West African outbreak, being detect-
able, at the best, in only one in every forty to fifty EVD
patients. These data are corroborated by another survey
which reported that there were only three subjects with
unexplained bleeding in a sample of 103 EVD patients in
Sierra Leone [58].
Such a huge decrease in ocular and orofacial EVD fea-
tures, which occurred during the West African outbreak,
parallels the significant decrease in case-fatality rate,
which fell by one third, from 65 % (95 % confidence
interval, 55–75 %) during the Eastern-Central African
outbreaks [31], to 47.0 % (95 % confidence interval,
46.2–47.9 %) in the West African outbreak –estimated
using data from Guinea and Sierra Leone reported by
the WHO [13]. In addition, during the West African
outbreak, the case-fatality rate progressively decreased in
rural areas starting from rates similar as those observed
in previous EVD outbreaks. This decrease is in line with
the hypothesis of the adaptation of Ebolavirus to the
human host [27], and is not in contrast with the indis-
putable excellent results due to the implementation of
control policies, such as the national strategy for the
Rapid Isolation and Treatment of Ebola (RITE) in
Liberia [62].
Another element supporting these results showing that
haemorrhagic features drastically decreased during the
West African outbreak, is that in 20 % EVD patients the
transmission route was unexplained [4]. This suggests
that in one fifth of transmissions, the signs and the
symptoms of EVD subjects who acted as infection
source were so slight that the infected person could not
remember the transmission event.
An element of debate is the meaning of the doubled
mutation rate of the Ebolavirus occurred during the
West African outbreak. According to two studies per-
formed on whole Zaire Ebolavirus genome and on GP
glycoprotein sequence, there were no signs of positive
selection, which would have definitively confirmed the
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human adaptation hypothesis [18, 19]. Conversely, most
studies considered as evident signs of selective pres-
sure events such as the emergence of multiple, even
intra-host, novel Ebolavirus lineages during the West
African outbreak, the many non-synonymous RNA
nucleotide changes leading to amino-acid changes,
some of them at positions of high level of conservation
across Eastern-Central African Ebolaviruses and the
positive selection within the GP glycoprotein amino-
acidic sequence, which was not reported during previ-
ous outbreaks [17, 23–25, 30, 63].
These data suggest that, although the above-mentioned
social determinants have been responsible for part of the
reduced case-fatality reported during the West-African
EVD outbreak, human adaptation, along with immune
evasion, may have occurred. Indeed, in the classification
of stages leading to endemic human pathogens from
animal pathogens, Ebolavirus was previously classified at
stage 3, that is, an animal pathogen that can undergo only
a few cycles of secondary transmission between humans,
so that occasional human outbreaks triggered by a pri-
mary infection soon die out. However, the West African
outbreak yielded the characteristics of a stage-4 pathogen,
that is, an infectious disease that exists in animals and that
infects humans cyclically by primary transmission from
animal host, but that also undergoes long sequences of
secondary transmission between humans, without the in-
volvement of animal hosts. Examples of stage-4 infectious
diseases are typhus, yellow fever and influenza A [32]. Ac-
cording to this theory of the animal origin of human path-
ogens, transitions from stage 3 to stage 4 frequently
occurred during human evolution. However, the major
barrier of such a transition is that animal pathogens need
long secondary transmission chains to evolve adaptation
to the novel host. This condition was prevented in the
case of EVD by the small size of human communities
where the outbreaks occurred. Indeed, Eastern/Central
African outbreaks took place in villages where the number
of susceptible hosts rapidly ended up, because susceptible
individuals died or became immune, as demonstrated by
the high case-fatality rate –as high as 80–90 %- and the
high immunization rate –as high as 30 %, in villages where
EVD outbreaks occurred [2]. However, according to this
theory, some external factors, such as frequent blood
exposures, presence of susceptible pools of immunosup-
pressed hosts (e.g., malnourished populations) and large
population sizes, may intervene to protract human-to-
human transmission chains, thus promoting the transition
from stage 3 to stage 4 [32].
In line with this theory and accounting for the re-
ported decreased proportion of EVD patients with
haemorrhagic symptoms, it is possible to conjecture
that the aforementioned West Africa-specific social
determinants have been responsible for the initially
high number of secondary (and undetected) transmis-
sions between humans [21]. Thanks to this long
human-to-human transmission cycle [10] the Ebolavirus
had the opportunity to adapt to the human host.
Conclusions
In conclusion, along with the increased Ebolavirus muta-
tion rate and the decreased case-fatality rate that occurred
during the West African outbreak, this outbreak was also
characterized by a significant decrease in the proportion of
patients with bleeding features. Some of these features, that
is, nasal and gingival bleeding almost disappeared. These
data support the hypothesis of Ebolavirus adaptation to
human host.
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